A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus

PHASE2CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Lupus Erythematosus, SystemicLupus
Interventions
DRUG

MEDI-545

100 mg once; SC Placebo × 12 doses on other weeks

DRUG

MEDI-545

100 mg every 4 weeks × 4 doses; SC Placebo × 9 doses on other weeks

DRUG

MEDI-545

100 mg every 2 weeks × 7 doses; SC Placebo × 6 doses on other weeks

DRUG

MEDI-545

100 mg every week × 13 doses

DRUG

Placebo

SC Placebo every week × 13 doses

Trial Locations (22)

10003

Research Site, Brooklyn

21205

Research Site, Baltimore

28210

Research Site, Charlotte

29204

Research Site, Columbia

29406

Research Site, Charleston

30033

Research Site, Decatur

30060

Research Site, Marrietta

30269

Research Site, West Fayetteville

30303

Research Site, Atlanta

34474

Research Site, Ocala

36207

Research Site, Anniston

45219

Research Site, Cincinnati

48910

Research Site, Lansing

73104

Research Site, Oklahoma City

77004

Research Site, Houston

77479

Research Site, Sugarland

80910

Research Site, Colorado Springs

91786

Research Site, Upland

92646

Research Site, Huntington Beach

98111

Research Site, Seattle

06030-5353

Research Site, Farmington

33765-2616

Research Site, Clearwater

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MedImmune LLC

INDUSTRY